CM336
Phase 3Small molecule
CM336 is one of 107 small molecule programs targeting POEMS syndrome. It is currently in Phase 3.
5
Indications
10
Total Trials
10
Active Trials
106
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1CM336
KKeymed Biosciences Co.Ltd
Phase 3
Ninlaro
TakedaPreclinical
Prolia
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Nolvadex
AstraZenecaPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Oblimersen Sodium
NNational Cancer Institute (NCI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma2 trials
Multiple Myeloma (MM)2 trials
A Phase Ib/II, Non-Randomized, Biomarker-Stratified Umbrella Study of Chemotherapy-Free Strategies in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Status: Sonrotoclax and a BCMA/CD3 Bispecific Antibody (AL-005)
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07687004·50 enrolled
Immune Thrombocytopenia1 trial
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06799611·20 enrolled
POEMS syndrome1 trial
BCMA/CD3 BsAb Therapy for POEMS Syndrome
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07115654·10 enrolled
3 more indications
Bispecific Antibody1 trial
BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07407010·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CM336. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKeymed Biosciences Co.Ltd